Robert Koch Strasse 50
Mainz 55129
Germany
49 6131 554 2860
https://mainzbiomed.com
Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 65
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Guido Baechler | CEO & Executive Director | N/A | N/A | 1965 |
Mr. William J. Caragol | Chief Financial Officer | N/A | N/A | 1967 |
Dr. Christopher Von Torne P.M.P., Ph.D. | Chief Operating Officer | N/A | N/A | 1972 |
Dr. Frank Krieg-Schneider | Chief Technology Officer | N/A | N/A | 1962 |
Dr. Moritz Eidens Ph.D. | Chief Science Officer & Executive Director | N/A | N/A | 1984 |
Stefan Erlach | Head of Human Resources | N/A | N/A | N/A |
Mr. Philipp Freese | Chief Business Officer | N/A | N/A | 1983 |
Mr. Darin S. Leigh | Chief Commercial Officer | N/A | N/A | 1968 |
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.